Septerna Names SEP-204 Development Candidate for Graves' Disease and TED; Phase 1 Set for Q1 2027
SEPN has more than doubled off its 52-week low of $17.55.
Summary
Septerna selected SEP-204, an oral TSHR inhibitor for Graves' disease and thyroid eye disease, as a development candidate and reported supportive preclinical data, with a Phase 1 trial planned to start in Q1 2027.
Key Events · Product Development and Regulatory · SEPN
-
SEP-204 Named Development Candidate
Septerna selected SEP-204, an oral small molecule TSHR negative allosteric modulator, as its development candidate for Graves' disease and thyroid eye disease.
-
Preclinical Data Show Reversal of Disease Signs
In a TSAb-driven mouse model, SEP-204 normalized T4 and reduced thyroid enlargement and orbital proptosis within 2 weeks; it is >1000x selective for TSHR over FSHR and LHR.
-
Phase 1 Start Planned for Q1 2027
A Phase 1 trial in healthy volunteers is anticipated to begin in the first quarter of 2027; a projected human half-life of ~20-40 hours supports once-daily oral dosing.
-
Cash Runway Into 2029 Reiterated
The updated corporate presentation states cash runway is expected to support operating plans at least into 2029, alongside lead programs SEP-479 (Phase 1 data expected Q1 2027) and SEP-631.
Analysis · SEPN · Life Sciences
Septerna has added a third wholly-owned clinical-stage asset: SEP-204, an oral TSHR negative allosteric modulator targeting Graves' disease and thyroid eye disease, a market of more than 2 million US Graves' patients where no new treatments have been approved in decades. For a first-in-class program, the preclinical package is credible: over 1000x selectivity versus related receptors, T4 normalization and reversal of thyroid enlargement and eye proptosis in a TSAb-driven mouse model, and a projected 20-40 hour human half-life that supports once-daily oral dosing. Value hinges on the Phase 1 start planned for Q1 2027, still roughly a quarter away and carrying the usual risk that preclinical findings do not translate to patients. The accompanying presentation also reiterates a cash runway into at least 2029, so this is pipeline expansion rather than a financing event.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SEPN was trading at $43.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $17.55 to $51.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.